Medivir Ab (0GP7)

Medivir Ab

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0GP7

1 2 3 4 Next >>

Date	Time	Source	Headline	Symbol	Company
15/01/2024	07:45	PR Newswire (US)	Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox	LSE:0GP7	Medivir Ab
04/01/2024	07:47	PR Newswire (US)	Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	LSE:0GP7	Medivir Ab
19/12/2023	07:54	PR Newswire (US)	Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan	LSE:0GP7	Medivir Ab
13/12/2023	10:12	PR Newswire (US)	Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval	LSE:0GP7	Medivir Ab
06/12/2023	11:20	PR Newswire (US)	Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway	LSE:0GP7	Medivir Ab
06/12/2023	07:44	PR Newswire (US)	Medivir to present at the Carlsquare Equity Research Investor Day	LSE:0GP7	Medivir Ab
01/12/2023	10:32	PR Newswire (US)	Bulletin from Extraordinary General Meeting in Medivir AB (publ)	LSE:0GP7	Medivir Ab
27/11/2023	08:52	PR Newswire (US)	Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC	LSE:0GP7	Medivir Ab
22/11/2023	07:46	PR Newswire (US)	Medivir to present at the Redeye Life Science Day	LSE:0GP7	Medivir Ab
21/11/2023	07:48	PR Newswire (US)	Medivir to present at the Erik Penser Bank Company Event	LSE:0GP7	Medivir Ab
13/11/2023	08:49	PR Newswire (US)	Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA	LSE:0GP7	Medivir Ab
07/11/2023	20:50	PR Newswire (US)	Notice of Extraordinary General Meeting in Medivir AB (publ)	LSE:0GP7	Medivir Ab
27/10/2023	07:01	PR Newswire (US)	MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023	LSE:0GP7	Medivir Ab
25/10/2023	06:46	PR Newswire (US)	Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday	LSE:0GP7	Medivir Ab
23/10/2023	06:48	PR Newswire (US)	Nomination Committee of Medivir appointed	LSE:0GP7	Medivir Ab
20/10/2023	13:29	PR Newswire (US)	Change in Medivir's Board of Directors	LSE:0GP7	Medivir Ab
16/05/2023	16:38	PR Newswire (US)	Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023	LSE:0GP7	Medivir Ab
04/05/2023	14:55	PR Newswire (US)	Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)	LSE:0GP7	Medivir Ab
04/05/2023	14:25	PR Newswire (US)	Resolutions at the Annual General Meeting in Medivir on 4 May 2023	LSE:0GP7	Medivir Ab
27/04/2023	07:06	PR Newswire (US)	MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2023	LSE:0GP7	Medivir Ab
17/04/2023	07:30	PR Newswire (US)	Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination	LSE:0GP7	Medivir Ab
04/04/2023	09:03	PR Newswire (US)	Medivir 2022 Annual Report published	LSE:0GP7	Medivir Ab
31/03/2023	10:25	PR Newswire (US)	Notice of Annual General Meeting of Medivir AB (publ)	LSE:0GP7	Medivir Ab
17/03/2023	08:01	PR Newswire (US)	Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR	LSE:0GP7	Medivir Ab
14/03/2023	08:18	PR Newswire (US)	First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®	LSE:0GP7	Medivir Ab
08/03/2023	15:08	PR Newswire (US)	Medivir to present at the Stockholm Corporate Finance Life Science Day	LSE:0GP7	Medivir Ab
23/02/2023	08:03	PR Newswire (US)	Medivir to present at the Erik Penser Bank Healthcare Day	LSE:0GP7	Medivir Ab
21/02/2023	08:54	PR Newswire (US)	Pia Baumann takes up her position as Chief Medical Officer	LSE:0GP7	Medivir Ab
20/02/2023	10:04	PR Newswire (US)	Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC	LSE:0GP7	Medivir Ab
15/02/2023	08:15	PR Newswire (US)	MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2022	LSE:0GP7	Medivir Ab